Next Phase Newsletter

A private investment firm based in Florida makes co-investments into early stage life science companies. The firm prefers to invest in Series A-B rounds, and does not make seed investments. The firm makes investments of up to $300,000 out of the firm’s own capital, and is also working with an international partner that makes investments of up to $30 million in medical devices. The firm invests in startups US-wide.

The firm invests broadly in the life sciences and will consider opportunities in therapeutics, devices, diagnostics, healthcare IT and life science tools. The firm’s partner org is focused on late stage opportunities in the electronic medical device sector and will invest up to $30 million in these opportunities, with an interest in opportunities in which this org can act as a manufacturing partner. In other sectors, the firm makes early stage investments in companies that have established proof of concept, and interests include orphan drugs, the microbiome, healthcare data science, tools and some devices.

The firm prefers to invest in companies that have already received a significant round of funding in the past. For data and healthcare IT companies, initial revenues are preferred. The firm focuses on opportunities that will provide a short path to exit. The firm takes an active role with portfolio companies, particularly in making strategic and market connections with partners in Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA, China, and India currently manages a fund with $125 million and is actively seeking investment opportunities across a wide range of industries. A significant allocation of the fund is dedicated to healthcare investments, while the rest of the fund will focus on investing in automation/robotics companies and relations to healthcare. On average, the size of investment is $2.5M. The firm seeks opportunities that provide some degree of investment loss protection through strong intellectual property. The firm can participate anywhere from Seed to Series B. The firm is willing to both lead and co-invest in companies located around the globe, with a preference in US, China, and Germany. The firm plans to make 6-8 investments per year but is flexible. The firm is actively seeking new investment opportunities.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, and Healthcare IT companies. The firm is open to all kinds of sectors and indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in medical devices and cardiovascular diseases. In terms of therapeutics, the firm will look at products of all stages from pre-clinical to phase III. Regarding medical devices and diagnostics, the firm will invest at any stage of development.

The firm will invest in privately held companies only. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases, but the firm prefers to have board observer rights in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Toronto-based life sciences venture capital firm with offices throughout USA and Canada manages over $250M and is currently investing from a new fund closed in 2017. The firm typically makes initial investments ranging from $2-$6 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months.

The firm invests primarily in Therapeutics and Medical Devices, with selective investments in diagnostic imaging and Healthcare IT. The firm is looking for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data.

The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A investment management firm based in China manages multiple funds and is engaged in equity investment, asset management, merger and acquisition across several industries, including healthcare. The firm’s healthcare portfolio includes Chase Sun Pharmaceutical, Lisheng Pharma, Tasly Pharm, Furui Medical Science, Zhongxin Pharmaceutical, and Tianyao Medical Industry. The size of investment varies depending on the deal, but the firm is investing from a 1 billion RMB fund for healthcare. The firm is currently seeking equity investment and licensing opportunities in China and the US. The firm is looking for companies with a China angle and has experience helping companies obtain CFDA approval.

Within healthcare, the firm is interested in medical devices, IVD, medical equipment, home-care products, and other healthcare-related technologies. The firm considers products that have at least completed prototype. The firm prefers products that have already obtained FDA clearance or approval, but it is happy to work with companies who are ~1 year away from FDA approval as well. In terms of indication areas, the firm is interested in diseases with large market potential in China, including oncology, reproductive health, cardiovascular diseases, and diabetes and metabolic disorders.

The firm seeks to work with experienced teams with strong sector knowledge. The firm is looking for products with a China angle and may request distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a Japan-based corporate with offices in Japan, China, India, and Silicon Valley makes seed, venture, and growth stage investments in companies in the life sciences space as well as other spaces like IT and cleantech. The firm typically makes equity investments in the range of $3-5M per portfolio company.

The firm primarily invests in life science companies based in the USA, but due to the firm’s global presence, the firm can also invest in companies based in China, Japan, India, and Europe. The firm has no current mandate for the number of allocations it plans to make in the space and will evaluate relevant opportunities as they surface.

The firm invests in early-stage companies in the biotech therapeutics, medical technology and devices, diagnostics, and healthcare IT sectors. The firm is sector and indication agnostic.

The firm is looking for companies with a strong and qualified management team or technical experts in the relevant technology. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm of a China-based company that that focuses on water treatment, sludge treatment, solid waste disposal, and special pump manufacturing, is currently operating a $25M USD fund and a $200M RMB fund that focus on cleantech, hardware, healthtech, and biotechnology. In addition, the firm is also in the process of developing a new acceleration program in the USA dedicated for cleantech innovations. Unlike many other corporate VC arms that have a slow internal investment process, the firm is able to proceed quickly with their decision making process.

The firm has invested in 10 companies since its establishment in 2017 and is actively seeking investment opportunities in the sectors mentioned above. The firm will initially invest up to $1M in equity. The firm works closely with the local government in China and utilizes domestic resources to support company growth in China, but China angle is not necessary for investment. The firm is open to companies globally.

The firm invests broadly in the life sciences and healthcare sectors, including therapeutics, medical devices, and diagnostics. However, the firm will most likely not invest in healthcare IT technologies. The firm is establishing a hospital in China and is most interested in technologies that could be integrated in hospital systems. The firm is agnostic in terms of the company’s stage of development.

The firm is interested in working with companies supported by an experienced management team with strong expertise. The firm is open to acting as a lead or co-investor and is capable of bringing other regional investment groups to syndicate rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm headquartered in Europe is exclusively focused on the development of oncology therapies. The firm makes selective investments in early-stage drug development companies targeting cancer therapies that can bring solid proof of concept to the table. Typically, the firm invests in incorporated companies from late seed stage to early series B. The investment size will vary, and it can range from a few hundred thousand dollars up to a couple of million dollars. The firm may make 3-4 investments in the next year, depending on the opportunity. The firm has no geographic restriction and is actively seeking new investment opportunities across the globe.

In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies, and is open to all types of therapeutic modalities and all indications within the oncology space, including platform technology that has a lead oncology therapeutic product. The firm will typically not invest in medical devices or diagnostics, unless as companion to a therapeutic solution. Project will be evaluated on solid preclinical proof-of-concept (late preclinical stage/pre-IND or early clinical), and will often fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa).

Representative portfolio companies include: a company developing small-molecule and antibody compounds targeting tumor related immune suppression, enhanced APC function and immune cell efficacy; a company developing novel immune modulating antibody therapeutics to harness the immune system against cancer; a spin-out company of a large pharmaceutical company developing a new generation of highly selective MET kinase activity inhibitors with augmented therapeutic index; a company developing hypoxia activated pro-cytotoxic small molecules; a company developing a versatile nanoparticle platform which allows payload delivery in the tumor micro-environment, etc.

The firm only invests in private companies with experienced management teams and breakthrough potential. The firm most often takes the responsibility to be lead investor, alone or in syndicate as the opportunity demands, and wants to be actively involved in the successful development and growth of the portfolio companies. To this end, the firm has a several experts in oncology, intellectual property and drug development on the investment team and available to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.